GSK's Tykerb again disappoints in adjuvant breast cancer setting
12 December 2011
Nancy Faigen
Please Login to read the full article.
12 December 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE still down on overall survival benefit of Roche's Herceptin and GSK's Tyverb following appeal
- GSK and Novartis withdraw EU filings in cancer and influenza
- NICE no for Tyverb and Herceptin in breast cancer, Roche considers appeal
- GSK curbs Tykerb against Herceptin but combo tests continue
FEATURES
Other Informa Features
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
